<DOC>
	<DOCNO>NCT01418794</DOCNO>
	<brief_summary>Polymer carry drug-eluting stent may increase inflammatory response thrombosis . Our previous study show polymer-free rapamycin-coated stent bring dose-dependent reduction restenosis . This prospective , multicenter , randomize control clinical trial aim explore efficacy safety YUKON drug elute stent diffuse coronary artery disease .</brief_summary>
	<brief_title>Efficacy Safety YUKON Drug Eluting Stent Diffuse Coronary Artery Disease</brief_title>
	<detailed_description />
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Age 1885 year old , male nonpregnant woman asymptomatic ischemia , stable unstable angina , old myocardial infarction patient least one target lesion length ≥ 20 mm ( Visual method ) Target lesion diameter 2.5mm4.0 mm ( Visual method ) Target lesion diameter stenosis ≥ 70 % Patients indication coronary artery bypass graft ( CABG ) surgery Patients voluntary , understand purpose study , willing accept angiography clinical followup Acute myocardial infarction le 1 week Bridge vascular disease Instent restenosis lesion Patient bleeding tendency , history active peptic ulcer , History cerebral hemorrhage subarachnoid hemorrhage , history stroke within half year , contraindication anticoagulant therapy antiplatelet Allergic aspirin , clopidogrel ticlopidine , heparin , contrast agent , rapamycin metal Life expectancy le 12 month Patient participate clinical trial meet deadline primary endpoint Poor patient compliance Heart transplant recipient Patient stent implant within 1 year Patient multivessel disease ( Long lesion ) already receive stent implantation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Acute Coronary Syndromes</keyword>
	<keyword>Drug elute stent</keyword>
	<keyword>Diffused lesion</keyword>
</DOC>